Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.

Area of Science:

• Clinical pharmacology and drug development
• Clinical trial methodology
• Regulatory science

Background:

• The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs).
• Existing evidence for DCT feasibility and benefits primarily comes from later-phase trials (Phase 2/3) and observational studies.
• Early drug development (Phase 1) faces unique challenges including patient accrual and safety monitoring.

Purpose of the Study:

• To explore the potential of decentralized models in Phase 1 clinical trials.
• To identify benefits of applying decentralized approaches to early drug development.
• To propose solutions for challenges hindering Phase 1 DCT implementation.

Main Methods:

• Review of published data on decentralized clinical trials.
• Analysis of feasibility and benefits in various trial phases.
• Development of an exploratory framework for Phase 1 DCTs.

Main Results:

• Decentralized Phase 1 trials can improve patient accrual by overcoming geographic barriers.
• DCTs can enhance patient population diversity, benefiting rare tumor research.
• Key challenges include safety monitoring, data integrity, product shipment, and administration.

Conclusions:

• Decentralized models offer significant advantages for Phase 1 clinical trials, including improved patient access and diversity.
• Addressing safety, data quality, and logistical challenges is crucial for successful Phase 1 DCT implementation.
• An exploratory framework is proposed to guide the conceptualization of decentralized Phase 1 trials.